View Older Stories View More Recent Stories

Nov 28, 2023 04:30PM AIM ImmunoTech Provides Update Regarding Annual Meeting
Nov 27, 2023 09:06AM AIM ImmunoTech (AIM) Bolsters Intellectual Property Estate for Ampligen with Issuance of Two Key U.S. Patents
Nov 27, 2023 09:05AM AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
Nov 14, 2023 10:00AM AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Trip
Nov 9, 2023 08:05AM AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
Nov 6, 2023 09:25AM AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
Sep 22, 2023 09:05AM AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Sep 5, 2023 09:05AM AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 23, 2023 08:00AM AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements
Aug 9, 2023 09:05AM AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
Jul 19, 2023 05:47AM AIM ImmunoTech (AIM) Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
Jul 18, 2023 07:30PM AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
Jun 27, 2023 11:16AM AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research
Apr 12, 2023 08:35AM AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
Apr 4, 2023 08:46AM AIM ImmunoTech (AIM) Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Apr 4, 2023 08:45AM AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Apr 3, 2023 06:30AM AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 30, 2023 08:45AM AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
Mar 27, 2023 09:05AM AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
Mar 16, 2023 08:45AM AIM ImmunoTech (AIM) Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
Mar 16, 2023 08:45AM AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
Mar 8, 2023 08:45AM AIM ImmunoTech (AIM) Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
Mar 8, 2023 08:45AM AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
Mar 6, 2023 08:45AM AIM ImmunoTech (AIM) Issues Letter to Stockholders
Mar 6, 2023 08:45AM AIM ImmunoTech Issues Letter to Stockholders
Feb 28, 2023 08:45AM AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
Feb 17, 2023 08:55AM AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
Jan 17, 2023 08:45AM AIM ImmunoTech (AIM) Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Jan 17, 2023 08:45AM AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Jan 9, 2023 08:05AM AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevent
Jan 5, 2023 08:45AM AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
Dec 12, 2022 09:01AM AIM ImmunoTech (AIM) Appoints Christopher McAleer, Ph.D. as Scientific Officer
Dec 12, 2022 09:00AM AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
Dec 8, 2022 08:05AM AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
Dec 2, 2022 10:45AM AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
Nov 15, 2022 07:00AM AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 14, 2022 07:00AM AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the T
Nov 9, 2022 09:00AM AIM ImmunoTech Announces Corporate Governance Enhancements
Nov 3, 2022 12:34PM AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting
Nov 2, 2022 07:14AM AIM ImmunoTech (AIM) Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease
Nov 2, 2022 07:05AM AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease
Oct 31, 2022 07:32AM AIM ImmunoTech (AIM) Announces Delaware Court Rules in Favor of it and Declines to Declare Activist Group’s Nominations Valid
Oct 31, 2022 07:30AM Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group’s Nominations Valid
Oct 26, 2022 05:13PM AIM ImmunoTech (AIM) Board Issues Letter to Shareholders
Oct 26, 2022 05:12PM AIM ImmunoTech Board Issues Letter to Shareholders
Oct 12, 2022 08:46AM AIM ImmunoTech (AIM) Announces FDA Clearance of IND Application for Phase 2 of Ampligen
Oct 12, 2022 08:45AM AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
Sep 21, 2022 08:45AM AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
Sep 19, 2022 08:05AM AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders
Sep 7, 2022 07:25AM AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference
View More Recent Stories View Older Stories